Our strategy and business model We are focused on delivering demonstrable value.
Effective treatments and services Commitment to superior treatments Improved public for their patients health and societal value Better lives for patients Superior clinical Brave culture driving evidence and clear innovation to deliver economic benets value to all Return to enable further investment Address symptomatic conditions with differentiated Our vision is to imagine and lead the future of treatments and services healthcare for people with life-altering We focus on treatments and services for symptomatic conditions in conditions, creating value for society.
We bring areas of high medical need, so patients experience a noticeable and ongoing improvement in their lives.
this vision to life through our strategy and Lead our markets business model.
We operate in specialist therapeutic categories where we believe we can lead the way in providing healthcare solutions and make a meaningful difference to patients.
Our strategy Research and develop new solutions effectively We seek to innovate both through our own Research and Our strategy describes how Development R&D and through our proven strategy of we will achieve our vision.
Our focus is on reaching faster decision points and using the best route, to develop the specialist Deliver demonstrable value treatments and services of the future for our patients.
We aim to deliver demonstrable value to all our stakeholders: Commit to continued growth patients, physicians, payors, policy makers, investors and Our growth fuels the creation of greater value for all our employees.
Earnings growth fuels future R&D investment.
Higher Put patients at the heart of everything we do returns to our shareholders fuels further investment in healthcare.
We strive to help our patients lead better lives.
This drives the value Further investment increases opportunities for our employees to we deliver to all our stakeholders.
Its a self-reinforcing circle of value.
provide new and better solutions for physicians and their patients.
10 Shire plc Annual Report 2012 Overview Sharing our culture of being brave Our business model Our culture of being brave is enormously important to us.
We model our culture on the bravery of our patients.
Our employees We implement our strategy through our strive to be as brave as the people we help and we believe that business model.
Its our structure for success makes a big difference.
Our employees are valuable to us they culturally, operationally, in terms of what we make the difference and we take great care in hiring and developing them.
offer, how we organise ourselves, where we Focusing in-house on our strengths focus our research and development and our We concentrate on what were best at.
Shire excels because we partnerships.
direct our internal efforts to what were good at.
We outsource non-core services and non-differentiated skills.
This enables us to Operating through three distinct, autonomous businesses stay the right size internally and focus on the right things to deliver To serve our different core patient groups, we have three significant value.
distinct businesses: Taking a selective approach to research and development Q Specialty Pharmaceuticals SP We balance our investment in R&D between early and late stage Q Human Genetic Therapies HGT development including leveraging proprietary technology platforms.
Q Regenerative Medicine RM We also balance in-house and outsourced R&D.
Our businesses each have their own commercial infrastructures Welcoming and embracing partnerships and dedicated R&D and supply chain management.
From academic institutions to start-ups to biotech companies and charitable organizations we place great emphasis on working in Seeking to meet our patients needs beyond core treatments partnership with others.
Talking to and working with those around In addition to helping patients by developing products to treat their us helps us identify and acquire diverse sources of ideas, symptoms, we also seek to provide complementary help and innovations and technologies.
Through partnerships we tap into the services, for example education programs and support for families best of the best and create value together.
Its a natural route for us to take in line with our commitment to deliver greater value to our patients.
17 projects in development of which 13 are in Phase 2 or beyond Imagine The world is changing, prov viding an opportunity for new idea as, approaches and solutions.
By changing in the right way we maintain n and live up to our role as an industr ry leader but more importantly offer p patients medicines and hope of a better life.
S S S S S S Sh Sh Sh Sh Sh S Sh S S S S S S S S Sh S S S S S S Shire hi hi hi hiiiiiiiire re re re re r re re re re re re r re re re r re r re re re e e e e e plc p p p plc plc plc plc plc plc plc p plc plc plc plc pl pl plc pl plc plc plc plc plc plc p plc plc pl plc plc plc plc p plc plc pl pl plc plc p p plc plc plc plc plc p p plc p plc p p p p p p p plc c c c c c c c c c c c c c c c c c c c c c c c c c c c c A An An An A A An An An An An An An An An An An An An An An An A An An An An An An A An An An An An A An A An An A An A A A A An A An An A A An A An n n n n n n n nnua nua nua nua nua nua nua nua nua nua nu nua nua nua nua nua nua nua nua nua nua nua n nua nua nu nua nua nua nua n n nua nua n nu nua nua nua n nua nua nua nua nu n n nua nua n nua n n n nua ua u u u ua u ua u u u ua ua u u u u ua u u ua a a a al R l R l R l R lR lR l R l R l R l R lR l R l R l R l R l R lR l R ll R l R l R llR l R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R R Rep ep ep ep e ep ep ep ep e ep ep ep ep ep ep ep ep ep ep ep e e ep ep ep ep ep ep ep ep ep e e ep ep e ep ep e e ep ep e e e e ep ep ep p po po po po p po po po po p po po p po p p po p p p po po o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o or rt rt rt rt rt rt rt rt rt rt rt rt rt rt rt r r rt rt rt rt rt rt rt rt rt rt rt rt rt rt r rt r rt r r r rt r rt rt r r r rt rt t t t 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 01 01 01 0 01 0 01 01 0 0 0 0 01 0 01 0 01 01 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 12 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 11
